IGC - IGC Pharma, Inc.

Day 1m 10m 60m PreMarket Market AfterHours Gap
0.35 -0.03 (-7.74%) --- 0.0 (0.0%) 0.0 (0.82%) -0.03 (-10.14%) 0.0 (1.5%) 0.0 (-0.74%) -0.01 (-3.85%)

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.02
Diluted EPS:
-0.02
Basic P/E:
-15.915
Diluted P/E:
-15.915
RSI(14) 1m:
100.0
VWAP:
0.32
RVol:

Events

Period Kind Movement Occurred At

Related News